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Variable patient responses to drugs are a key issue for medicine and for drug
discovery and development. Personalized medicine, that is the selection of medicines
for subgroups of patients so as to maximize drug efficacy and minimize toxicity, is
a key goal of twenty-first century healthcare. Currently, most personalized medicine
paradigms rely on clinical judgment based on the patient’s history, and on the analysis
of the patients’ genome to predict drug effects i.e., pharmacogenomics. However,
variability in patient responses to drugs is dependent upon many environmental factors
to which human genomics is essentially blind. A new paradigm for predicting drug
responses based on individual pre-dose metabolite profiles has emerged in the past
decade: pharmacometabonomics, which is defined as “the prediction of the outcome
(for example, efficacy or toxicity) of a drug or xenobiotic intervention in an individual
based on a mathematical model of pre-intervention metabolite signatures.” The new
pharmacometabonomics paradigm is complementary to pharmacogenomics but has the
advantage of being sensitive to environmental as well as genomic factors. This review will
chart the discovery and development of pharmacometabonomics, and provide examples
of its current utility and possible future developments.
Keywords: metabonomics, metabolomics, pharmacometabonomics, pharmacometabolomics, personalized
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INTRODUCTION
Many patients experience little or no efficacy, or even suffer toxicity, when prescribed drugs today.
A 1998 study by Pomeranz et al. estimated that in US hospitals in 1994, over 2 million patients had
serious adverse drug reactions (ADRs) requiring hospitalization, producing permanent disability,
or in an estimated 106,000 cases, that led to death (Lazarou et al., 1998). This is a shocking state of
affairs given the advances in twenty-first century medicine. It is estimated that the cost to the US
economy of ADRs is between $30 and $100 billion per year (Lee et al., 2014).
Abbreviations: 1H, hydrogen-1; GC, gas chromatography; GDM, genetically determined metabotype; GWAS, genome-
wide association studies; HPLC, high performance liquid chromatography; JRES, J-resolved; LC, liquid chromatography;
MS, mass spectrometry; MVA, multivariate (statistical) analysis; NMR, nuclear magnetic resonance; PCA, principal
components analysis; PK, pharmacokinetics; PLS, projection to latent structures (partial least squares), SNP, single nucleotide
polymorphism; TOF, time-of-flight; UPLC, ultra performance liquid chromatography.
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There is thus a clear need to be able to personalize medicine
to ensure that patients are prescribed medications that will be
both efficacious and free of noxious side-effects. Personalized
medicine has many definitions including “Application of
genomic and molecular data to better target the delivery of
healthcare, facilitate the discovery and clinical testing of new
products, and help determine a person’s predisposition to a
particular disease or condition” (Abrahams et al., 2005). It
is also known as precision medicine, stratified medicine, or
individualized medicine. A simpler definition would be “the
use of genomic, molecular, and clinical information to select
medicines that are more likely to be both effective and safe for
that patient” (Everett et al., 2016). Personalized medicine has
a long history, as all good physicians and clinicians will tailor
their treatments and medication prescription to the needs of
the individual patient. However, since the sequencing of the
human genome completed, there has been a growing interest
in the analysis of human genetic variations, particularly single
nucleotide polymorphisms (SNPs), and the correlation of those
variations with drug efficacy and safety. There have also been
significant developments in the association of genetic variation
with differing metabolite profiles or metabotypes (Holmes et al.,
2008) between individuals, in genome-wide association studies
(GWAS).
Pharmacogenomics is the study of how genetic variation
modulates drug responses between individuals and evidence
has accumulated of the involvement of over 2000 genes in
drug responses (Salari et al., 2012). However, the successful
use of pharmacogenomics in the clinic has been limited
(Urban and Goldstein, 2014) and recent reviews of the
use of pharmacogenomics in randomized clinical trials in
cardiovascular disease (Joseph et al., 2014), type-2 diabetes
(Maruthur et al., 2014), and depression (Perlis, 2014) have failed
to show clear value.
In principle there are several reasons why pharmacogenomics
studies on their own may struggle to predict drug responses in
humans: (1) drug absorption, metabolism, and excretion will
be subject to environmental factors such as diet, the use of
alcohol, the taking of other medications, and the status of the
patient’s microbiome (Holmes et al., 2012); (2) the detection
of upstream genetic differences in a patient indicates that
there may be alterations in the patient’s downstream metabolic
phenotype, not that there necessarily will be: there is not always
a fixed relationship between altered genotype and expression of
phenotype, and (3) the issue of phenoconversion, induced by
drug co-administration (Shah and Smith, 2015), where a genetic
extensive metabolizer can be converted into a phenotypic poor
metabolizer and thus confound a pharmacogenomics analysis.
In this situation, the use of metabolic profiling to predict
drug efficacy and safety has a number of notable advantages.
Firstly, the metabolic phenotype reflects the actual physiological
status of the patient in real time, not some future possible state.
Secondly, metabolic profiling has the ability to be sensitive to
both genetic and environmental factors, including the status of
the gut microbiome, that are critical for phenotype expression.
Metabolic profiling of biological fluids, tissues and other
samples using various technologies has a history that goes
back at least several decades (Lindon and Wilson, 2016). The
use of these approaches increased significantly in the 1980s
with the advent of advanced pulsed Fourier transform nuclear
magnetic resonance (NMR) spectroscopy (Lindon et al., 1999)
and hyphenated mass spectrometry (MS) (Theodoridis et al.,
2011) analytical technologies capable of profiling dozens to
hundreds ofmetabolites in biological fluids such as urine or blood
plasma. Early applications were established in the investigation
of drug metabolism (Everett et al., 1984), toxicology (Holmes
et al., 1992), inborn errors of metabolism (Iles et al., 1985) and
the understanding of disease states (Bales et al., 1984). Metabolic
profiling is now termed metabonomics or metabolomics (Lindon
et al., 2007).
Metabonomics1 has the following interventional definition:
“the quantitative measurement of the multiparametric metabolic
response of living systems to pathophysiological stimuli or
genetic modification” (Lindon et al., 2000). The alternative term
metabolomics was coined by Fiehn et al. (Fiehn, 2002) and
given the following observational definition: “a comprehensive
analysis in which all the metabolites of a biological system are
identified and quantified.” The latter definition is potentially
less useful due to both its observational nature and the
near impossibility of identifying, let alone quantifying, all the
metabolites in a complex biological system. Originally the
terms were distinct with metabonomics being used for studies
of biofluids and tissues, particularly using NMR detection
methodologies, and metabolomics being used for studies of plant
and cellular metabolites, particularly by MS. The two terms are
nowadays used inter-changeably: we will use the original term
metabonomics throughout.
The two main technologies used for metabolic profiling
studies are NMR spectroscopy and MS, the latter usually in
a hyphenated mode with a separation technology such as gas
chromatography (GC), high performance liquid chromatography
(HPLC), or ultra performance liquid chromatography (UPLC).
The key features of these technologies are briefly summarized in
Boxes 1, 2 and the interested reader is referred to consult further
literature (Lindon et al., 1999, 2007; Theodoridis et al., 2011;
Dona et al., 2016).
Irrespective of the detection technology used, multivariate
statistical analysis (MVA) methods will probably be needed in
order to analyse the complex spectra from a metabolic profiling
experiment and to determine statistically significant differences
between the spectra of, for instance, different groups of patients.
These MVA methods are in two main classes: (i) unsupervised
methods such as principal components analysis (PCA), where the
class of the samples e.g., patients dosed with drug X or patients
dosed with placebo, is unknown to the MVA algorithm and
(ii) supervised methods, such as projection to latent structures
(PLS), where the class of the samples is used as an input to
the algorithm. In the case of supervised MVA methods, care
must be exercised to avoid over-fitting of the data, and external
1The concept of metabonomics arose in 1996 in the course of a collaboration
between Jeremy Nicholson at Birkbeck College, University of London and Jeremy
Everett at Pfizer Global R & D, in order to provide a framework for the biofluid
NMR spectroscopy elements of a series of what would now be called multi-omics
or pan-omics studies using genomics, proteomics, clinical chemistry, and biofluid
analyses in an integrated fashion to discover novel, early, drug safety biomarkers.
Metabonomics was chosen as the etymologically-preferred term.
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BOX 1 | NMR Spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy is the most powerful method for the elucidation of the structure of small molecules in solution and it has an important
role in the detection, identification, and quantification of metabolites in biological samples, especially in biological fluids. In a typical one-dimensional NMR experiment
a sample of a biofluid in a glass tube would be inserted into a probe placed in a strong [usually 14.1 Tesla (T) or above] and highly homogeneous magnetic field
that would induce an alignment of NMR-active nuclei with the magnetic field direction. A short (typically microseconds duration) radiofrequency pulse of the correct
power and frequency for a given NMR-active nucleus is then applied to the sample which causes the NMR-active nuclei to move out of alignment with the magnetic
field. The relaxation of these excited nuclei back to their ground state induces an oscillating electric current in the receiver coils of the probe of the spectrometer
that decays, typically over a few seconds. Fourier transformation of this time-domain free induction decay signal gives rise to the familiar frequency-domain NMR
spectrum in which signal intensity is plotted as a function of nuclear resonance frequency. The most commonly studied NMR-active nucleus is the proton, 1H, which
is the most sensitive non-radioactive nucleus and is the workhorse of metabonomics studies. Through the use of a reference standard, typically 3-(trimethylsilyl)-
2,2′,3,3′-tetradeuteropropionic acid (TSP) or deuterated forms of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) or its sodium salt, the NMR frequencies of the
protons / hydrogen atoms are converted into a dimensionless chemical shift measured in parts per million relative to the reference. This chemical shift is constant,
no matter what the magnetic field strength.
The 1H NMR spectrum of a biofluid has some remarkable properties:
1. Each chemically non-equivalent hydrogen atom in a metabolite will resonate at its own individual chemical shift which is determined by the chemical nature of that
hydrogen and its neighboring atoms in the metabolite and by the solution environment of the sample.
2. Each individual hydrogen atom in a metabolite gives rise to a signal that has an area proportional to the relative concentration of that metabolite in the sample i.e.,
given certain provisos, 1H NMR spectroscopy is a fully quantitative technology and the signal area for a CH2 group in a metabolite will be exactly double that of
the signal area for a CH moiety in that same metabolite. NMR spectroscopy is thus an excellent, quantitative, non-selective detector, and the 1H NMR spectrum
of a biofluid will generally equate to the sum of the NMR spectra of all the component metabolites, in proportion to their concentrations in the sample.
3. The nuclei of neighboring, non-equivalent hydrogen atoms in a metabolite will spin-couple to one another, giving rise to 1H NMR signal splittings (also known as
J-couplings) that are critical for metabolite identification and structure elucidation. These signal splittings or multiplicities obey an n + 1 rule in first order spectra,
where n = the number of equivalent neighboring protons. For instance in the 1H NMR spectrum of lactic acid, CH3-CH(OH)-CO2H, the CH3- methyl group
protons will resonate as a 2-line, 1:1 intensity doublet (1 + 1 = 2) at 1.33 ppm due to it having one neighboring hydrogen on the adjacent CH group. By contrast
the CH proton will resonate as a 4-line, 1:3:3:1 intensity quartet (3 + 1 = 4) as it has three equivalent hydrogen neighbors. The intensity patterns obey Pascal’s
triangle. The size of the splittings is also informative and depends on the distance in bonds between the coupling hydrogens and their chemical, stereochemical,
and conformational properties. Typically, 2-bond couplings, 2JH,H between non-equivalent hydrogens on the same carbon atom are larger in size than 3-bond
couplings, 3JH,H, between hydrogens on adjacent carbons, and coupling over 4-bonds or more are generally much smaller.
Many nuclei including 12C and 16O are NMR-inactive and this may appear to be a disadvantage but in fact, this helps simplify the NMR spectra of metabolites, which
would otherwise be hugely complex and difficult to interpret. In metabolite identification, use is made however of the fact that the 1.1% natural abundance 13C isotope
is NMR-active, and although insensitive to direct detection, can be readily observed via indirect detection through the 1H nucleus. This is important as the chemical
shift range in 13C NMR is 20 times that of 1H NMR and thus much more sensitive to subtle changes in metabolite structure. Two-dimensional NMR experiments (see
below) that correlate proton chemical shifts with those of directly bonded or more remote carbons are particularly important in metabolite identification.
Huge advances have been made in NMR spectroscopy in the past several decades due to the development of:
1. Higher magnetic fields enabling greater sensitivity and higher signal dispersion.
2. 2-dimensional NMR spectroscopy enabling the spreading out of the NMR spectra of complex samples such as biofluids into a second frequency dimension and
the automated correlation of through-bond or even through-space connectivities between NMR-active nuclei, critical to metabolite identification.
3. Cryo-cooled probes giving much higher spectral sensitivity due to the reduction in thermal noise.
4. Automated and highly stable, digital NMR spectrometers giving unmatched reproducibility, quality, and throughput.
The Achilles heel of NMR spectroscopy has been and still is low sensitivity, due to the fact that the signal in NMR comes only from the tiny fraction of nuclei that are in
excess in the nuclear magnetic ground state at spin equilibrium. In general the detection limits are in the range mM to uM whereas MS-based techniques like LC-MS
can detect metabolites in the range mM down to pM.
validation of results with an independent cohort of samples
is best practice. Analysis of metabolic profiling data will often
start by using an unsupervised method and especially PCA to
provide: (i) an overview of the spread of the samples in metabolic
space, (ii) a visualization of any separation in metabolic space
between subgroups of samples, and (iii) the identification of any
significant outliers in the data. In PCA, the algorithm will take
linear combinations of the input variables, such as NMR signal
intensities, to form a series of principal components (PCs). Each
successive PC will explain a decreasing amount of the variance
in the data set and will be orthogonal to the preceding PCs. The
PCA scores plot shows the relationships between the samples in
the study across typically two or three PCs. The loadings plot
shows which variables in the input data are contributing the
variance observed between the samples. See Figure 1 below for an
example of the use of PCA. The interested reader can find further
information in the recent literature (Lindon andNicholson, 2008;
Robinette et al., 2013).
THE DISCOVERY OF
PHARMACOMETABONOMICS IN ANIMALS
AND HUMANS
The Discovery of Preclinical
Pharmacometabonomics
Irreproducibility of results was a source of concern in some
early metabonomics experiments, particularly those involving
metabolic profiling of animals in drug safety or drug metabolism
studies. The biofluid metabolite profiles from different animals
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BOX 2 | Mass Spectrometry (MS)
MS is used as the other main detection technology for metabolic profiling experiments. Mass spectrometers measure the mass-to-charge ratios of charged molecular
ions or molecular ion fragments following their ionization in an ion source. In general, MS detection follows a hyphenated, on-line separation step such as GC, HPLC,
or UPLC, so that fewer components are introduced into the mass spectrometer at the same time, reducing ionization suppression effects.
After separation by HPLC or UPLC, metabolites are ionized, typically using an ionization technology such as electrospray and often utilizing both positive and negative
ion generation and detection. Electrospray ionization (ESI) is a soft ionization method that results in few fragment ions. In the positive ionization mode, ESI+, it will
usually give protonated molecular ions [M+ H]+, or salt or solvent adducts thereof as the most intense ions in the spectrum. In cases where metabolites are unstable,
for instance exhibiting a tendency to dehydrate, it is common to observe protonated, dehydrated molecular ion fragments, [M + H − H2O]
+. Correspondingly in
negative ion mode the ES- spectrum will consist largely of deprotonated molecular ions or ion complexes.
Separation of metabolites by GC will generally require derivatisation of the metabolites in order to make them volatile enough to travel through the GC column. This
can introduce issues of variable metabolite derivatisation both in terms of the efficiency of derivatisation between different metabolites and the possibility that some
individual metabolites may exhibit mono-, di-, or poly-derivatisation, resulting in multiple molecular species and spectral interpretation complexity. In GC-MS mode,
electron impact ionization is often used, which is a hard ionization technique generating a much greater degree of fragmentation in the mass spectrum and enabling
the use of MS libraries for metabolite identification.
The hyphenated mass spectra of a biofluid sample will have the following characteristics:
1. Elution of metabolites from the separation technology at characteristic retention times, allowing confirmation of metabolite identity based on chromatographic
retention time, assuming that authentic reference standards of the metabolite are available.
2. Presence of molecular ion, molecular ion adduct or fragment ions that can be characteristic for the metabolite giving rise to them, in terms of mass-to-charge
ratios.
3. If experiments are conducted under conditions of high resolution, molecular formula information can be derived on the molecular ions and fragments.
4. Quantitation of a metabolite can be challenging unless a reference standard of the metabolite is available.
5. Sensitivity of metabolite detection is very high: mM down to pM and much superior to NMR spectroscopy.
6. Run-to-run reproducibility is lower than for NMR spectroscopy, due to direct introduction of samples into the spectrometer and the variability that that generates
in the spectrometer, particularly in ionization efficiency.
MS is thus highly complementary to NMR spectroscopy and the two technologies are often most powerful when used in concert. Although MS is not a universal
detector like NMR spectroscopy, its high sensitivity is a key factor that dictates it choice in many metabolic profiling experiments.
in the same group on the same study would sometimes be
so strikingly different that the competence of the technicians
involved in drug dosing would be questioned. Sometimes,
these effects were ascribed to “biological variation,” whatever
that was. In the course of a large collaboration between
Pfizer Global R & D and Imperial College London, the
groups of Nicholson, Everett and co-workers, particularly John
Lindon, Claude Charuel and Andy Clayton, were pursuing the
discovery of early biomarkers of drug toxicity. At a meeting
at Pfizer Amboise, France on October 18th 2000, the topic
of significantly divergent rat urine metabolite profiles was on
the agenda: in one study some rats appeared to excrete very
large quantities of drug-related metabolites whereas others
excreted almost none. During that meeting, the then radical
idea was formulated that the post-dose differences between rats
in the same group were linked to differences in their pre-dose
metabolic status. Experiments were designed to test these ideas
in animals and then humans and they were found to hold:
pharmacometabonomics was discovered (Everett et al., 2016) and
is now showing promise to help deliver personalized medicine in
the future.
In order to test the hypothesis that the post-dose response
of an animal to drug dosing could be influenced by its pre-
dose metabolic status, a series of experiments were designed
and conducted, including one key experiment involving the
dosing of acetaminophen (paracetamol), a widely prescribed oral
analgesic, to rats. The experimental hypothesis was that the
analysis of pre-dose metabolite profiles should enable a degree
of prediction of the subsequent metabolism of the drug and of
its toxicity (Clayton et al., 2006). Pre-dose and post-dose urine
was collected from 65 rats given a single oral dose of paracetamol
(600mg/kg in an aqueous suspension): a further 10 rats were in a
control group (suspension vehicle only). Following unsupervised
principal component analysis of the pre-dose urine NMR spectra,
a statistically significant association was shown between the
score for principal component 2 and the post-dose mean liver
histopathology score (r = −0.34, p = 0.007). In addition, a
statistically significant but partial PCA separation between rats in
liver histopathology class 1 (no or minimal necrosis) and class 3
(moderate necrosis) was confirmed with a Mann-WhitneyU-test
(n= 32, p= 0.002, Figure 1).
A statistically significant and validated model was also built
using the supervised multivariate technique projection to latent
structures (PLS, partial least squares), to predict the post-
dose molar ratio of the metabolite paracetamol glucuronide
to parent paracetamol (G/P) from the pre-dose metabolite
profile. Variable influence on projection analysis showed that
the most significant factor underlying this model was a positive
correlation between G/P and the integral (signal area) of the
region from 5.14 to 5.06 ppm in the pre-dose urine 1H NMR
spectra, the region where the signals for ether glucuronides
occur. The conclusion drawn was that the post-dose ratio of
G/P was at least partly controlled by the ability to form
ether glucuronides such as paracetamol glucuronide prior to
dosing (Clayton et al., 2006). The publication also included
preliminary pharmacometabonomics data on the prediction of
toxicity in rats dosed with allyl alcohol and galactosamine
hydrochloride. Pharmacometabonomics was defined as “the
prediction of the outcome (for example, efficacy or toxicity) of
a drug or xenobiotic intervention in an individual based on a
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FIGURE 1 | Unsupervised PCA of the pre-dose urines of rats dosed
subsequently with paracetamol. (A) PCA Scores plot of the multivariate
analysis of the binned 600 MHz 1H NMR spectra of the pre-dose rat urine.
Each diamond corresponds to a different animal color-coded according to its
mean, post-dose liver histopathology score (MHS): Class 1, no or minimal liver
necrosis, green; Class 2, mild necrosis, blue, and Class 3, moderate necrosis,
red. A partial separation is observed across PC2 between Class 1 and Class 3.
(B) A plot of MHS against PC2: a weak but significant correlation is observed.
(C) PCA Scores plot for the 1H NMR spectra of the pre-dose rat urine, with
the same color-coding as in (A) for Classes 1 and 3 only: the partial separation
across PC2 is more readily observed. (D) The PCA loadings plot showing the
bins of the 1H NMR spectrum of the pre-dose urine that are responsible for
the separations across PC2 and the direction of influence. Tau, taurine; Citr,
citrate; Oxog, 2-ketoglutarate; TMAO + Bet, trimethylamine-N-oxide (TMAO)
and betaine. Numbers correspond to the 1H NMR chemical shifts (ppm) at the
center of the bin responsible for the separation. Figure reproduced from
Nature Publishing Group (Clayton et al., 2006).
mathematical model of pre-intervention metabolite signatures.”
Pharmacometabonomics is defined as a prognostic or predictive
methodology, in contrast to metabonomics/metabolomics which
is a diagnostic methodology.
The Discovery of Pharmacometabonomics
in Humans
Important as the results in rats were, the Pfizer-Imperial
College team had as the ultimate goal, the demonstration of
pharmacometabonomics in humans, with the aim of developing
new approaches to personalized medicine. Following the positive
pre-clinical results, a clinical experiment in 99 human volunteers
was designed and ethically approved, involving oral dosing of
paracetamol/acetaminophen. The research hypothesis of this
experiment was that the pre-dose urinary endogenous metabolite
profiles of the volunteers would be correlated with the post-dose
differences in the metabolism of the drug. Paracetamol is a widely
used analgesic that is principally metabolized to both sulfate and
glucuronide metabolites in humans (Figure 2).
However, significant variability in the metabolism of the drug
has been reported (Patel et al., 1992). Pre-dose, 0–3 and 3–6 h
post-dose urines were collected from volunteers who were given
a standard oral dose of paracetamol (2× 500mg tablets) with 250
ml water. The volunteers were not on a standard diet but were
only eligible for the study if not taking drugs, herbal medicines or
dietary supplements, and restrictions were placed on their diet
and alcohol intake. Both the pre-dose endogenous metabolite
profiles and the post-dose drug metabolite profiles were analyzed
using 600 MHz flow-mode 1H NMR spectroscopy of the urine
samples. Figure 3 shows 1H NMR spectra of both pre-dose and
post-dose urines of two of the volunteers.
Two observations are of interest: firstly, volunteer 2 excretes a
much higher ratio of paracetamol sulfate (S, metabolite 7) relative
to paracetamol glucuronide (G, metabolite 8) in the 0–3 h post-
dose urine and secondly volunteer 2 has no signal observable at
ca 2.35 ppm in the pre-dose urine spectrum, whereas volunteer 1
has a clear and distinct signal in this region (metabolite 4).
Further analysis of the spectra from all remaining volunteers
showed that there was a clear relationship between the presence
of the signal from unknown endogenous metabolite 4 in the pre-
dose urines and the ratio of S/G drugmetabolites in the post-dose
urines (Figure 4).
If the pre-dose ratio of unknown metabolite 4 normalized to
creatinine was >0.06, then the post-dose ratio of S/G was always
<0.8. However, if the pre-dose ratio of 4, normalized to creatinine
was <0.06, then the post-dose ratio of S/G took a wide range of
values and was not predictable. A similar pattern was obtained
after analysis of the 3–6 h post-dose urines. AMann-Whitney test
showed the statistical significance of the distribution of the high
metabolite 4 to creatinine group (25 subjects) at both timepoints
(p = 1.0 × 10−4 for S/G at 0–3 h and p = 1.2 × 10−4 for S/G at
3–6 h post dose). With a Bonferroni correction of 100 to mitigate
for multiple hypothesis testing the p-value for 95% confidence is
0.05/100= 5× 10−4 (Clayton et al., 2009).
It thus became imperative to identify unknown metabolite
4, which appeared to be a pre-dose biomarker capable of at
least partial prediction of the post-dose ratio of paracetamol
metabolites. Metabolite 4 exhibited a singlet resonance at ca
2.35 ppm which was assigned to a methyl group connected
directly to an sp2 hybridized carbon atom. The singlet was
associated with a pair of second-order, pseudo-doublet, aromatic
proton resonances at ca 7.21 and 7.29 ppm. It was thus deduced
that metabolite 4 was a 4-disubstituted toluene. Metabolite 4 was
positively identified as 4-cresyl sulfate (Figure 5) by chemical,
spectroscopic and enzymatic methods (Clayton et al., 2009).
The identification of the biomarker as 4-cresylsulfate came
as a shock as this is not wholly a human metabolite. It is a
bacterial/human co-metabolite that is produced by the human
sulfation of 4-cresol, which is itself a metabolite originating in
the gut microbiome, particularly from some Chlostridia species
of bacteria (Smith and Macfarlane, 1997). In order to gain
confidence in the findings, the entire NMR analysis was repeated
in 2007, 4 years after the original analysis but using NMR tubes
instead of a flow probe: no significant changes to the results were
found. In addition, in 2008, the original NMR-based analysis of
S/G for the 3–6 h post-dose urines was repeated using UPLC-MS
with a correlation coefficient of 0.99 and no outliers (quantitation
from online UV detector).
The rationalization of the results obtained in this paracetamol
pharmacometabonomics experiment is as follows. Unlike
mice and rats that can metabolites 4-cresol by sulfation
or glucuronidation, humans metabolize 4-cresol largely by
sulfation. In a person with a gut microbiome excreting large
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FIGURE 2 | The molecular structures of paracetamol and its principal human metabolites.
amounts of 4-cresol, the sulfation of this toxin to 4-cresylsulfate,
metabolite 4, may use up a large part of the limited sulfation
capacity of that individual. If that person is subsequently
challenged with a large dose of a drug, such as paracetamol,
requiring metabolism by sulfation, then the body will use
glucuronidation to a greater extent instead, to make up for its
diminished sulfation capacity. The situation is particularly acute
for paracetamol and 4-cresol, as they will not only utilize the
same sulfotransferase enzyme co-factor, 3′-phosphoadenosine
5′-phosphosulfate, which is known to be in limited supply
(Coughtrie, 2002) but, due to structural similarity, they will
also be in competition for the same sulfotransferase enzymes
(see Figure 5; Gamage et al., 2006). Interestingly a recent study
showed that germ-free mice exhibited a higher S/G ratio after
dosing paracetamol than conventionally-housed mice; a result
consistent with the findings in humans (Possamai et al., 2015).
The outcome of this experiment is significant (Wilson, 2009):
1. It represents the first demonstration of
pharmacometabonomics in humans and provides a biological
rationale for the observed inter-individual differences in drug
metabolism.
2. It demonstrates that inter-individual variation in response
to drug therapy is significantly influenced by the person’s
biochemical status and not just their genotype.
3. It shows the significant effect that the gut microbiome can
have on personalized medicine for the first time.
Since many other important drugs are metabolized by sulfation,
this result is expected to have significance beyond paracetamol. In
addition, since sulfation is an important element of many human
biochemical processes, further implications of inter-individual
4-cresol excretion from the microbiome are likely. Finally,
many diseases are linked to altered levels of 4-cresylsulfate
or to altered S/G ratios post paracetamol dosing, indicating
that there may be a microbiome involvement in these diseases
(Clayton et al., 2009).
PROGRESS IN
PHARMACOMETABONOMICS IN ANIMALS
AND HUMANS
Since the discovery of pharmacometabonomics in animals
(Clayton et al., 2006) and in humans (Clayton et al., 2009),
progress in the field has been rapid. To date a total of ca
30 studies in animals and humans have been described in 36
papers (Table 1: some studies have been the subject of multiple
publications). All studies up to ca 2014 have been recently
reviewed (Everett et al., 2013; Everett, 2015), to which the
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FIGURE 3 | 600 MHz 1H NMR spectra of the urine from two different
human volunteers in the region from 0.5 to 8.0 ppm, with expansion of
the aromatic proton region (7.0–8.0 ppm) and a higher field region
(2.0–2.8) shown above. (A) Pre-dose urine from volunteer 1; (B) 0–3 h
post-dose NMR spectra from volunteer 1, The main differences between the
pre-dose and post-dose spectra are the appearance of signals from
paracetamol and its metabolites in both the aromatic and acetyl regions. (C,D)
Corresponding pre- and post-dose spectra for volunteer 2. Key to peak
numbers: 1, creatinine; 2, hippurate; 3, phenylacetylglutamine; 4, metabolite 4
(unknown at the time: see text); 5, citrate; 6, cluster of N-acetyl groups from
paracetamol-related compounds; 7, paracetamol sulfate; 8, paracetamol
glucuronide; 9, other paracetamol-related compounds. Reproduced from
PNAS (Clayton et al., 2009).
interested reader is referred, so this review will focus on more
recent developments.
The majority of pre-clinical studies on animals have focused
on the prediction of adverse events. One recent publication
in this area by Dai et al has shown that survival and non-
survival in rats treated with lipopolysaccharide can be predicted
using an LC-MS- and GC-MS-based approach (Dai et al.,
2016). A pre-dose serum model based on the predictive
biomarkers sphingosine, sphinganine, palmitic acid, oleic acid,
FIGURE 4 | The relationship between the 0–3 h post-dose ratio of
paracetamol sulfate to paracetamol glucuronide (S/G) and the
pre-dose ratio of metabolite 4, normalized to creatinine in the urines
from human volunteers on the paracetamol trial. Adapted from PNAS
(Clayton et al., 2009).
and cholesterol was generated and various hypotheses on the
influence of inter-individual lipid metabolism differences on
survival were proposed.
Far more publications have emerged recently demonstrating
success with pharmacometabonomics approaches in human
volunteer and patient studies.
Huang et al. used GC-MS analysis of predose plasma samples
from 48 hospitalized, healthy Chinese volunteers to predict
pharmacokinetic (PK) properties of atorvastatin, a lipid-lowering
agent known to have significant inter-individual PK variation
(Huang et al., 2015). In this study, a 15-fold variation in
Cmax and a 12-fold variation in the total drug area under
the curve (AUC) were observed. Projection to latent structures
(PLS) multivariate analysis methods, with both internal and
external validation, were used to show that a set of 17 and 12
endogenous pre-dose plasma metabolites were able to predict
Cmax and AUC, respectively. Molecules such as 2-hydroxybutyric
acid and cholesterol were found to be important components
of both the Cmax and AUC model. It was rationalized that
this may be because of competition between these endogenous
metabolites and atorvastatin for monocarboxylate and organic
anion transporters.
Kienana et al. used similar methodology, including external
validation, to predict methotrexate clearance in a group of 62
patients with lymphoid malignancies, treated with a high dose
methotrexate (>1 g.m−2; Muhrez et al., 2016). Methotrexate is
an interesting example as genetic polymorphisms in enzymes
or transporter proteins involved in methotrexate clearance
are known to be associated with PK variation. However,
it is striking that significant course-to-course variability in
methotrexate PK in the same patients also occurs, which means
that environmental factors are also critical (Muhrez et al., 2016).
A good prediction of methotrexate clearance was obtained (mean
prediction error and precision for patients not in the model
group were 0.4 and 21%, respectively) from a model based
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FIGURE 5 | The chemical structures of 4-cresol and its sulfation
product, 4-cresylsulfate (metabolite 4) compared with the structures of
paracetamol and paracetamol sulfate.
on 28 pre-dose urinary metabolites, including valerylglycine, 2-
methylacetoacetic acid, and gentisic acid (2, 5-dihydroxybenzoic
acid). Again, the model was thought to provide information
on the status/ability of transporter systems in the patient
pre-dose. Less good statistics were obtained for prediction
of delayed elimination: 93% of normal eliminators (excellent
specificity) but only 42% of the delayed eliminators were
correctly predicted (poor sensitivity). Low numbers of delayed
eliminators in the patient cohort prevented further model
optimization.
Weinshilboum and Kaddurah-Daouk and co-workers
have developed the concept of pharmacometabonomics-
informed pharmacogenomics. In this approach, metabolite
biomarkers found to be predictive of drug outcomes in
pharmacometabonomics experiments are used as the starting
point for focused pharmacogenomics experiments. The
approaches used include: (i) searching for single nucleotide
polymorphisms in genes related to the synthesis, transportation,
and degradation of metabolites found to be discriminating
biomarkers in pharmacometabonomics experiments and (ii)
the use of genotype imputation (Ji et al., 2011; Abo et al.,
2012). This is an important new approach to the use of
pharmacometabonomics (Neavin et al., 2016). The same group
has recently followed up with a pharmacometabonomics
informed pharmacogenomics study on patients with major
depressive disorder (MDD) in the Pharmacogenomics Research
Network Antidepressant Medication Pharmacogenomics Study
(PGRN-AMPS). Predose plasma serotonin levels were associated
with both remission and response at both 4 and 8 weeks
after initiation of MDD patient treatment with citalopram or
escitalopram. Baseline serotonin concentrations were then used
as a phenotype for genome-wide association studies (GWAS).
The GWAS study showed a genome-wide statistically significant
SNP cluster on chromosome four 5′ of TSPAN5 and a cluster
across ERICH3 on chromosome one. Both knockdown and
over-expression of these genes in a neuroblastoma cell line
significantly altered the expression of four serotonin pathway
genes. It was concluded that TSPAN5 and ERICH3 were
associated with plasma serotonin concentrations and may be
involved in selective serotonin reuptake inhibitor treatment
efficacy (Gupta et al., 2016).
Kapoor et al. used 1H NMR spectroscopy to analyse pre-
dose urine samples from a small number of rheumatoid
arthritis patients being treated with anti-tumor necrosis factor
agents (infliximab or etanercept; Kapoor et al., 2013). Both
unsupervised (PCA) and supervised (PLS) multivariate analysis
methods indicated that baseline urine metabolites discriminated
between patients who either did, or did not, have a good
response to anti-TNF therapy, according to European League
Against Rheumatism criteria (sensitivity 89%, specificity 86%).
Key metabolites responsible for the discrimination included
histamine, glutamine, xanthurenic acid, and ethanolamine. It
was proposed that the strong discriminator histamine may be
a urinary biomarker for inflammation or may report on the
breakdown of histidine. Repetition of the results in a larger cohort
was recommended.
Karas-Kuželicˇki et al. utilized a highly targeted and
hypothesis-driven approach to investigate if S-adenosyl
methionine (SAM) could be predictive of thiopurine-S-
methyltransferase (TPMT) phenotype (Karas-Kuželicˇki et al.,
2014). Inter-individual dosing of 6-mercaptopurine in the
treatment of childhood acute lymphoblastic leukemia is thought
to be dependent upon TPMT phenotype, although measurement
of TPMT pre-treatment and TPMT genotyping have been shown
to be not as useful as hoped, with concordance between genotype
and phenotype being as low as 50% in some TPMT-heterozygous
cohorts. SAM is known to be associated with TPMT activity
as it is a cofactor known to bind to the enzyme and can thus
potentially influence its activity. From a set of 19 biochemical and
10 hematological parameters, and after correction for multiple
hypothesis testing, only TPMT genotype (p = 1 × 10−13) and
SAM levels (p = 1 × 10−13) were found to be significantly
associated with TPMT activity in analyses of 1017 donors to
the Estonian Biobank. In TPMT -heterozygous patients with
normal TPMT activity, high SAM levels explained the disconnect
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TABLE 1 | The use of pharmacometabonomics to predict drug efficacy, toxicity, metabolism, and pharmacokineticsa.
Class of experiment Human studies Pre-clinical studies
Prediction of
pharmacokinetics (PK)
Prediction of tacrolimus PK in healthy volunteers (Phapale et al., 2010) Prediction of pharmacokinetics of triptolide in rats
(Liu et al., 2012)
Prediction of atorvastatin pharmacokinetics in healthy volunteers (Huang et al., 2015)
Prediction of methotrexate clearance in patients with lymphoid malignancies (Muhrez
et al., 2016)
Prediction of drug
metabolism
Prediction of metabolism of paracetamol/acetaminophen in human volunteers
(Clayton et al., 2009)
Prediction of paracetamol/acetaminophen
metabolism in rats (Clayton et al., 2006)
**First demonstration of pharmacometabonomics in humans **First demonstration of
pharmacometabonomicsPrediction of CYP3A4 induction in volunteer twins (Rahmioglu et al., 2011)
Prediction of CYP3A activity in healthy volunteers (Shin et al., 2013)
Prediction of drug
efficacy
Prediction of antipsychotic effects with olanzapine, risperidone and aripiprazole
(Kaddurah-Daouk et al., 2007)
**First detection of metabolic efficacy markers in baseline human samples
but study was small and designated hypotheses generating rather than
definitive by the authors
Prediction of simvastatin efficacy in patients on the Cholesterol and
Pharmacogenomics study (Kaddurah-Daouk et al., 2010; Trupp et al., 2012)
Prediction of citalopram/escitalopram response in patients with major depressive
disorder (MDD; Ji et al., 2011)
**First demonstration of pharmacometabonomics-informed
pharmacogenomics approach to personalized medicine (Abo et al., 2012) and
(Gupta et al., 2016)
Prediction of sertraline and placebo responses in patients with MDD
(Kaddurah-Daouk et al., 2011), (Kaddurah-Daouk et al., 2013), and (Zhu et al., 2013)
Prediction of efficacy of anti-psychotics in schizophrenia patients (Condray et al.,
2011)
Prediction of response to aspirin in healthy volunteers (Lewis et al., 2013;
Yerges-Armstrong et al., 2013; Ellero-Simatos et al., 2014)
Prediction of efficacy with anti-TNF therapies in rheumatoid arthritis (Kapoor et al.,
2013)
Prediction of thiopurine-S-methyltransferase phenotype in Estonian volunteers
(Karas-Kuželicˇki et al., 2014)
Prediction of efficacy of L-carnitine therapy for patients with sepsic shock (Puskarich
et al., 2015)
Prediction of acamprosate treatment outcomes in alcohol-dependent patients (Nam
et al., 2015)
Prediction of blood pressure lowering in hypertensive patients treated with atenolol
and hydrochlorothiazide (Rotroff et al., 2015)
Prediction of response in lung cancer patients (Hao et al., 2016)
Prediction of patient response to trastuzumab-paclitaxel neoadjuvant therapy in
HER-2 positive breast cancer (Miolo et al., 2016)
Prediction of adverse
events
Prediction of weight gain in breast cancer patients undergoing chemotherapy (Keun
et al., 2009)
Prediction of toxicity from
paracetamol/acetaminophen dosing in rats
(Clayton et al., 2006)**First demonstration of pharmacometabonomics in patients
Prediction of liver injury markers in patients treated with ximelagatran (Andersson
et al., 2009)
Prediction of onset of diabetes in rats administered
with streptozotocin (Li et al., 2007)
Prediction of toxicity of paracetamol/acetaminophen (“early-onset
pharmacometabonomics”) (Winnike et al., 2010)
Prediction of nephrotoxicity of cisplatin in rats
(Kwon et al., 2011)
Prediction of toxicity in patients with inoperable colorectal cancer treated with
capecitabine (Backshall et al., 2011)
Prediction of toxicity of isoniazid in rats
(Cunningham et al., 2012)
Prediction of variability in response to
galactosamine treatment in rats (Coen et al., 2012)
Prediction of toxicity from lipopolysaccharide
treatment in rats (Dai et al., 2016)
aSignificant papers are highlighted with a double asterisk with explanatory text in bold blue font.
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between genotype and phenotype. It was concluded that in the
future it would be reasonable to measure SAM levels only in
TPMT-mutated patients. In addition, it was proposed that SAM
supplementation to TPMT-mutated patients with low SAM levels
could reduce the incidences of side effects of 6-mercaptopurine
(Karas-Kuželicˇki et al., 2014).
Inter-individual patient differences have been an issue for
sepsis therapeutics. Puskarich et al. described an untargeted
1H NMR spectroscopy pharmacometabonomics approach to
determine differences in pre-dose serum metabolite levels
between survivors and non-survivors from a pilot, phase I,
placebo-controlled clinical trial of L-carnitine in 31 sepsis
patients (Puskarich et al., 2015). Amongst many results, baseline
concentrations of 3-hydroxybutyrate (p < 0.001), acetoacetate
(p < 0.001) and 3-hydroxyisovalerate (p < 0.001) were all
significantly lower in survivors of the therapy. Low ketone body,
L-carnitine-treated patients also showed a trend toward lower 1
year mortality than any other group (chi square p = 0.038). It
has been reported that the accumulation of ketone bodies, such
as 3-hydroxybutyrate and acetoacetate, may indicate impaired
metabolic functioning in sepsis. It was concluded that whilst
further, larger studies were needed, pharmacometabonomics
approaches could help in delivering precision medicine to sepsis
patients.
Alcohol use disorder (AUD) is also a complex and
heterogeneous disorder with significant patient variation. Nam
et al used UPLC-MS/MS analysis of patient serum in a
targeted approach to determine pre-dose biomarkers that would
distinguish responders (complete alcohol abstinence) from non-
responders (any alcohol usage) during 12 weeks of treatment with
oral acamprosate in 120 alcohol-dependent subjects (Nam et al.,
2015).
Acamprosate is known to reduce glutamate levels in the
brain. This study therefore profiled 36 metabolites, including 20
amino acids and determined that pre-dose glutamate levels were
significantly higher in 51 responders (32.3± 2.4 µM) than in the
39 non-responders (23.1 ± 1.7 µM, Wilcoxon rank sum test, p
= 0.012) in the discovery cohort. In the replication cohort, the
baseline glutamate levels were again higher in the responders (n
= 20) than the non-responders, n = 10, p = 0.036). No impact
of depression was found upon the baseline glutamate results.
Serum glutamate levels were normalized in the responders after
12 weeks of therapy but were unchanged in the non-responders.
Baseline serum ammonia levels were also significantly higher in
the responders in the discovery cohort (p = 0.003) and trended
higher (but not significantly) in the replication cohort. Baseline
glutamate to glutamine ratios were significantly higher in the
entire cohort of responders (n= 71) vs. non-responders (n= 49,
p = 0.016). A significant drop in glu/gln ratios was seen in
responders after acamprosate treatment p < 0.0001), whereas
no effect was seen in the non-responders. Consistent with this
finding, significant correlations were found between baseline
glutamate and glutamine synthetase activity (R2 = 0.13, p <
0.05), and between baseline ammonia and glutamine synthetase
activity (R2 = 0.09, p < 0.05) in the responders, but not the
non-responders. Additional studies showed that in the absence
of alcohol in mice, acamprosate enhances glutamine synthetase
production of glutamine from glutamate and ammonia. It was
concluded that a pharmacometabonomics approach involving
measurement of pre-treatment glutamate levels could be a useful
new method for personalized treatments of AUD patients with
acamprosate (Nam et al., 2015).
Rotroff et al. used untargeted GC-time of flight MS
to analyse plasma samples from patients enrolled in the
Pharmacogenomic Evaluation of Antihypertensive Responses
study at the University of Florida (Rotroff et al., 2015). One
hundred and twenty-eight White and one hundred and twenty-
nine black participants were randomly assigned to receive
atenolol therapy whilst 123 white and 83 black participants
were randomly assigned to hydrochlorothiazide therapy for
hypertension. Baseline metabolite profiles were significantly
different between the black and white patients (Wilcoxon rank
test, p < 0.001), which dictated the study analysis by race.
Baseline plasma levels of several metabolites, some unknown,
were significantly associated with changes in home diastolic
blood pressure (HDBP) in all, white and black patients on both
drugs. False discovery rate was used to correct for multiple
hypothesis testing with p < 0.05 and q < 0.2 considered
significant i.e., the chance of the low p-value being a false
discovery is <20%. One unknown, 223548, was positively
associated with HDBP change in white patients treated with
hydrochlorothiazide (p = 0.007, q = 0.15) but negatively
associated in black patients (p = 0.004, q = 0.11). This is either
a significant effect or possibly a false discovery. Multivariate
models were built using a discovery set and a validation set
(to avoid over-fitting) to predict HDBP response from baseline
plasma metabolite levels. Models for all treatments/all patients;
atenolol/all patients; hydrochlorothiazide/all patients and all
treatments/white patients were statistically significant for both
the discovery and validation sets. It was concluded that whilst
additional studies were needed, pharmacometabonomics may
have a significant role to play in helping deliver personalized
medicine for hypertensive patients in the future.
There have also been recent developments in the use of
pharmacometabonomics in the development of personalized
medicine approaches for the treatment of cancer. Hao et al. have
reported a pilot 1H NMR spectroscopy and GC-MS study of the
serum of treatment-naive, non-metastatic lung cancer patients
treated with standard chemotherapy, with and without radiation
(Hao et al., 2016). The GC-MS analysis enabled the construction
of an orthogonal PLS discriminant analysis (O-PLS-DA) model
(n= 25, cross-validated ANOVAR2= 0.39,Q2= 0.29, p= 0.034)
that showed that, amongst other differences, low pre-treatment
levels of hydroxylamine, tridecan-1-ol, octadecan-1-ol were
associated with survival. The GC-MS analyses provided better
prognostic data, whilst the 1H NMR data provided better tumor
diagnostic data. It was hypothesized that the biomarker alcohols
Frontiers in Pharmacology | www.frontiersin.org 10 September 2016 | Volume 7 | Article 297
Everett From Metabonomics to Pharmacometabonomics
are ketogenic substances and are deuterium depleted, eventually
giving rise, via mitochondrial processing, to deuterium depleted
“metabolic water” with a potential impact on macromolecule
synthesis and cell replication (Hao et al., 2016).
Miolo et al. used an LC-MS/MS approach to identify
biomarkers of response to trastuzumab-paclitaxel neoadjuvant
therapy in 34 HER-2 positive breast cancer patients (Miolo
et al., 2016). Histological analysis was used to categorize the
patients into good responders (pathological complete response,
n = 15) and poor responders (partial pathological response,
n = 19). Supervised PLS-DA multivariate analysis was used
to show that pre-treatment serum levels of spermidine were
significantly higher in the good responders (0.15 ± 0.06mM)
vs. the poor responders [0.09 ± 0.032 mM (p < 0.001,
q < 0.05)], whereas pre-treatment levels of tryptophan were
significantly lower in the good responder group (61.19 ±
8.46mM) vs. the poor responder group [73.82 ± 9.23 mM
(p = 0.001, q < 0.05)]. Amongst other possibilities, it was
hypothesized that high levels of spermidine could boost tumor
cell replication and thus enhance paclitaxel activity, whilst
low levels of typtophan may be associated with immune
suppression and enhancement of tratuzumab activity (Miolo
et al., 2016).
NOT PHARMACOMETABONOMICS!
It is worth noting that several publications claiming to report
pharmacometabonomics studies appear instead to be diagnostic
metabonomics studies reporting the effects of drugs onmetabolite
profiles. These studies contain no predictive or prognostic
elements and the literature is becoming confused by the mis-
naming of such studies. These recent papers appear to be
examples of this phenomenon (Park et al., 2013; Wikoff et al.,
2013; Serrano-Contreras et al., 2016).
PREDICTIVE METABONOMICS
Pharmacometabonomics is defined as “the prediction of
the outcome (for example, efficacy or toxicity) of a drug
or xenobiotic intervention in an individual based on a
mathematical model of pre-intervention metabolite signatures.”
At the time of its discovery (Clayton et al., 2006), it was
already envisaged that the prediction of drug effects via
pharmacometabonomics was just one example of a broader
set of predictive methodologies that we now call predictive
metabonomics, where the intervention could be broader than
just drug treatment, for instance, diet change, physical stress,
medical interventions or, just the passage of time. Predictive
metabonomics has been defined simply as “the prediction
of the outcome of an intervention in an individual based
on a mathematical model of pre-intervention metabolite
signatures” (Everett, 2015). Many excellent examples of
predictive metabonomics have been demonstrated recently and
some of these are directly relevant to personalized medicine
as, for example, they enable the prediction of individuals who
will in the future develop a particular disease vs. those who
will not.
Wang et al. used LC-MS to determine that higher baseline
plasma levels of leucine, isoleucine, valine, phenylalanine, and
tyrosine were predictive of subjects in the FraminghamOffspring
Study who went on to develop diabetes over a 12 year period
(p = 0.001 or lower). The predictive model was replicated in
the Malmo Diet and Cancer Study for all amino acids except
isoleucine (p-values 0.009–0.04; Wang et al., 2011).
Wang-Sattler et al. also used LC-MS and flow injection
analysis-MS to show that lower baseline serum levels of glycine,
lysophosphatidylcholine (LPC) (18:2) and acetylcarnitine were
predictive of the development of impaired glucose tolerance over
a 7 year period and that lower baseline serum levels of just glycine
and lysophosphatidylcholine (LPC) (18:2) were predictive for the
onset of type 2 diabetes over the same period (Wang-Sattler et al.,
2012).
Several other examples were recently reviewed (Everett et al.,
2016). In addition to these examples, Sjöberg et al. used GC-MS
to demonstrate that serum myo-inositol levels, sampled 3 or 7
days after symptom onset were predictive of delayed neurological
deficit as measured by the Glasgow Outcome Scale, 1 year after
subarachnoid hemorrhage (Sjöberg et al., 2015).
McPhail et al. used a combined 1H NMR spectroscopy
and UPLC-TOF-MS approach to demonstrate that levels of
lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs),
and lipids were reduced and levels of lactate, tyrosine,
methionine, and phenylalanine were increased in the plasma
of 18 out of 80 decompensated liver cirrhosis (DC) patients
who failed to survive 90 days post-admission (McPhail et al.,
2016). The outcome from the MVA were: three component
OPLS-DA (R2X = 0.57, R2Y = 0.46, Q2Y = 0.39) with
100% sensitivity and 85% specificity, CV-ANOVA 10−6. DC
Patients were defined as those with an acute episode of
variceal bleeding, jaundice, encephalopathy, ascites, sepsis, or
renal dysfunction requiring admission to hospital. A separate
cohort of 59 DC patients was used to externally validate this
model: sensitivity 98% (87–100%), specificity 89% (67–99%),
positive likelihood ratio 9 (3–34), negative likelihood ratio 0.03
(0.004–0.2), AUROC 0.96 (0.90–1.00), and a further cohort of
42 cirrhosis patients provided further confirmation of the 90
day mortality prediction model (McPhail et al., 2016). It was
hypothesized that the lower levels of LPCs and PCs reflected
increased liver damage and necrosis. Similarly, the increased
levels of lactate and the amino acids were noted to reflect liver
damage and failure. The fact that the model performed so well
in double external validation is very encouraging and it is hoped
that this new approach may have clinical utility in the short
term.
GENOME-WIDE ASSOCIATION STUDIES
(GWAS)
A number of important studies have been published establishing
linkages between genetic variation, metabolic phenotype and
disease risk or drug effect variation. Using a UPLC-MS and GC-
MS approach, Suhre et al. identified 37 genetic loci associated
with serum metabolite concentrations in participants from the
German KORA F4 (n = 1768) and British TwinsUK (n = 1.052)
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studies (Suhre et al., 2011a). Another study by Suhre et al using
a 1H NMR approach in a different cohort reported five new loci
with very significant associations (p-values < 3 × 10−19) with
metabolite concentrations (genetically determined metabotypes,
GDMs) with three of the loci previously associated with clinical
outcomes, including SLC7A9 for chronic kidney disease, NAT2,
for coronary artery disease and SLC6A20 for iminoglycinuria
(Suhre et al., 2011b).
A large study by Kettunen et al identified 31 genetic loci
with significant associations with human serum 1H NMR-
based metabolite levels in a GWAS of 8330 Finns genotyped
and imputed at 7.7 million SNPs (Kettunen et al., 2012).
The heritability of the metabolite measures was assessed using
intra-pair metabolite correlations for 221 monozygotic and 340
dizygotic twins from the Finnish Twin Cohort and was estimated
as varying between 23 and 55% for amino acids and other
small molecules, 48–62% for lipids and 50–76% for lipoproteins.
Examples of key loci identified include SLC25A1 with citrate,
DHDPSL with glutamine and SLC1A4 with valine.
Rhee et al. reported a GWAS of 217 MS-detected, human
plasma metabolites in 2076 participants of the Framingham
Heart Study. Estimated heritability was found to explain >20%
of inter-individual variation (Rhee et al., 2013). A total of
23 previously unidentified genetic loci associated with plasma
metabolites were discovered.
Shin et al. reported a large GWAS reporting significant
genome-wide, associations between 145 loci and >400
metabolites, using GC-MS/MS and LC-MS/MS analysis of serum
and plasma from 7824 adults from the KORA and TwinsUK data
sets (Shin et al., 2014). The study comprehensively linked the
resulting data with information on gene expression, heritability,
and overlap with previously identified genetic loci for diseases,
inborn errors of metabolism and pharmacological targets. A
powerful network model of genetic and metabolic associations
was built. The contribution of metabolic loci to variance in
metabolite concentrations was in the range 1–62% with a median
value of 6.9%.
Rueedi et al. described a GWAS linking genetic variation with
human urine 1H NMR metabolite features in 835 Caucasians
from the CoLaus study (Rueedi et al., 2014). Out of 139
discovered associations, 56 replicated and the identity of the
underlying metabolites was sought from the NMR features using
a new metabomatching method. In this way, SNP rs281408 in
FUT2was significantly associated with fucose concentrations and
a linkage with Crohn’s disease established.
It is clear that GWAS studies such as these, and other related
studies (Nicholson et al., 2011) will have a significant role to play
in the understanding of the origin of inter-individual variance
in metabolite concentrations and on the relative roles of genetic
and environmental factors to such variation. These studies will
undoubtedly help reach the goal of personalization of medicine
in the future.
CONCLUSIONS
Metabonomics is a young, diagnostic science that was defined<2
decades ago (Lindon et al., 2000) but it has already spawned a
new prognostic methodology, pharmacometabonomics, defined
as: “the prediction of the outcome (for example, efficacy or
toxicity) of a drug or xenobiotic intervention in an individual
based on a mathematical model of pre-intervention metabolite
signatures” (Clayton et al., 2006), that has shown great promise in
predicting the efficacy, safety, metabolism, and pharmacokinetics
of drugs prior to dosing. Most of the studies published to date
are relatively small pilot studies, but larger, externally validated
studies are emerging more recently: the study by McPhail et al.
demonstrating external validation in two independent cohorts
of a model for the prediction of survival in decompensated liver
cirrhosis patients is a landmark (McPhail et al., 2016).
Pharmacometabonomics is expected to work well
together with pharmacogenomics and the landmark
pharmacometabonomics-informed pharmacogenomics study
of Abo et al. demonstrated the power of these two technologies
working together in concert (Abo et al., 2012). The development
of many genome wide associations between genetic variation,
metabolic phenotype and disease risk, or drug response
variability is an important development in this area and is
expected to help interpret the results of both pharmacogenomics
and pharmacometabonomics experiments.
It is exciting to see the emergence of the new field of
predictive metabonomics, where the effects of interventions
broader than just drug treatment can be predicted. Remarkable
predictions of disease onset have been achieved, sometimes
predicting events that occur years after the baseline metabolic
profile measurements.
Another exciting development is that of longitudinal
pharmacometabonomics, where the journey of a patient through
a clinical episode can be tracked and predictions of best treatment
options made (Nicholson et al., 2012).
The development and coordinated use of all these methods
is poised to impact upon the improved delivery of personalized
medicine for patients, as pharmacogenomics on its own is likely
to be insufficient to fully deliver the promise of optimized
treatment for specific sub-groups of patients. It is envisaged that
pharmacometabonomics in concert with pharmacogenomics and
metagenomic analysis of patient microbiomes will provide the
wealth of relevant data necessary to make critical personalized
decisions for patient healthcare. That future is now close
to us.
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